Valeant posts 36% growth amid pricing scrutiny; may sell neurology biz

Carly Helfand

 may be the subject of current government , and it may have recently suffered a stock-price freefall. But the company gave investors some good news Monday with earnings that beat their mark.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS